Aleix Prat: The high costs of anticancer therapies in the USA

Aleix Prat shared the following on X:

“The high costs of anticancer therapies in the USA: challenges, opportunities, and progress in Nature Reviews Clinical Oncology.

Addressing the financial burden requires collaboration across healthcare. Equally important is investing in diagnostic tools to better tailor treatments and improve outcomes.

Read more.”

The high costs of anticancer therapies in the USA: challenges, opportunities and progress

Authors: Shelley A. Jazowski, Rahul K. Nayak & Stacie B. Dusetzina

Source: Aleix Prat/X

Aleix Prat is the Director of the Cancer Institute at Hospital Clinic of Barcelona, Head of the Translational Genomics Group at IDIBAPS, and a Professor at the University of Barcelona. He is also a Co-Founder of REVEAL GENOMICS, S.L. His work focuses on breast cancer genomics and the development of omics-based assays for clinical application. His expertise lies in breast cancer and gene expression profiling.